- Home
- JFU vs CVKD Comparison
JFU vs CVKD Comparison
Compare JFU & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- CVKD
- Stock Information
- Founded
- JFU 2006
- CVKD 2022
- Country
- JFU China
- CVKD United States
- Employees
- JFU N/A
- CVKD N/A
- Industry
- JFU Finance: Consumer Services
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- JFU Finance
- CVKD Health Care
- Exchange
- JFU Nasdaq
- CVKD Nasdaq
- Market Cap
- JFU 17.9M
- CVKD 20.8M
- IPO Year
- JFU 2019
- CVKD 2023
- Fundamental
- Price
- JFU $1.50
- CVKD $16.17
- Analyst Decision
- JFU
- CVKD Strong Buy
- Analyst Count
- JFU 0
- CVKD 2
- Target Price
- JFU N/A
- CVKD $46.00
- AVG Volume (30 Days)
- JFU 11.6K
- CVKD 79.1K
- Earning Date
- JFU 01-03-2025
- CVKD 11-07-2024
- Dividend Yield
- JFU N/A
- CVKD N/A
- EPS Growth
- JFU N/A
- CVKD N/A
- EPS
- JFU 0.09
- CVKD N/A
- Revenue
- JFU $40,614,155.00
- CVKD N/A
- Revenue This Year
- JFU N/A
- CVKD N/A
- Revenue Next Year
- JFU N/A
- CVKD N/A
- P/E Ratio
- JFU $16.09
- CVKD N/A
- Revenue Growth
- JFU N/A
- CVKD N/A
- 52 Week Low
- JFU $1.13
- CVKD $5.40
- 52 Week High
- JFU $3.85
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- JFU 48.81
- CVKD 61.78
- Support Level
- JFU $1.46
- CVKD $10.65
- Resistance Level
- JFU $1.60
- CVKD $12.25
- Average True Range (ATR)
- JFU 0.11
- CVKD 1.68
- MACD
- JFU 0.01
- CVKD 0.32
- Stochastic Oscillator
- JFU 47.22
- CVKD 76.54
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.